LumiThera, Inc.

LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases, specifically dry age-related macular degeneration (AMD).

LumiThera is the leader in ophthalmic photobiomodulation (PBM) innovation with its flagship product, the Valeda® Light Delivery System. Multiwavelength Valeda treatments are for patients suffering from dry AMD. The Food & Drug Administration (FDA) has authorized marketing of Valeda treatment for dry AMD patients to improve vision. Valeda is CE Marked in the EU and available in select countries in Latin America. 

AdaptDx Pro® is a portable dark adaptometer that utilizes AI to deliver a uniform patient experience. Impaired dark adaptation is the earliest biomarker of AMD and can be detected three years before clinical presentation. AdaptDx Pro is available in the U.S. and Canada.

NOVA Vision Testing System is a comprehensive electrophysiology platform that provides objective assessment of the entire pathway for visual and neuro-visual disorders. VEP is available in the U.S. and select countries outside of the U.S. ERG is only available outside of the U.S.

For more information on Valeda, visit www.lumithera.com. AdaptDx Pro and NOVA are available through LumiThera Diagnostics, Inc. and Diopsys, Inc., respectively.